Rapamycin (Sirolimus) Geriatric (65+) Dosing

Why Age 65+ Changes the Sirolimus Equation

Older adults are not simply smaller adults with a slower metabolism. After age 65, hepatic CYP3A4 activity declines by roughly 30%, glomerular filtration rate drops an average of 0.7 to 1 mL/min per year, and total body water decreases, all of which alter sirolimus pharmacokinetics in ways that matter clinically 1.

Sirolimus is metabolized almost entirely by CYP3A4 in the gut wall and liver, then effluxed by P-glycoprotein 2. Any age-related reduction in either pathway extends the drug's effective half-life. Published pharmacokinetic data place the mean half-life in older renal transplant recipients at 73 to 79 hours, compared with approximately 62 hours in adults under 40 3.

What This Means Practically

A 68-year-old receiving the standard 2 mg/day transplant maintenance dose may accumulate trough concentrations 40 to 60% higher than a 35-year-old on the same regimen. Starting dose should therefore be conservative, and the first trough check should occur no later than day 5 after initiation.

The Polypharmacy Problem

The average American aged 65 to 79 takes 4 to 5 prescription drugs simultaneously 4. Sirolimus has a narrow therapeutic index and is a substrate for both CYP3A4 and P-glycoprotein. Commonly co-prescribed geriatric drugs, including diltiazem, fluconazole, and erythromycin, can raise sirolimus blood levels 3- to 10-fold without dose adjustment 5. Any new prescription added to a stable sirolimus regimen should prompt a trough recheck within 5 to 7 days.

FDA-Approved Transplant Dosing in Geriatric Patients

The FDA-approved prescribing information for sirolimus (Rapamune, Pfizer) does not specify a separate geriatric dose but states explicitly that "greater sensitivity of some older individuals cannot be ruled out" 6. Current practice, reflected in the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 transplant guideline, uses whole-blood trough concentration targets rather than fixed mg/kg doses precisely because of inter-individual variability 7.

Loading Dose Considerations

For renal transplant, the approved loading dose is 6 mg on day 1, followed by 2 mg/day. In patients over 65, many transplant centers omit or halve the loading dose to avoid acute toxicity, particularly stomatitis and thrombocytopenia, which resolve more slowly in older patients.

Trough Target Ranges by Phase

| Phase | Target Trough (ng/mL) | Rationale | |---|---|---| | Months 1 to 3 (with calcineurin inhibitor) | 4 to 12 | Combined immunosuppression, higher rejection risk | | Months 4 to 12 | 4 to 8 | Reduced calcineurin inhibitor, stable graft | | Beyond 12 months | 4 to 6 | Minimize metabolic and pulmonary toxicity |

Staying below 8 ng/mL after the first year reduces the risk of sirolimus-associated pneumonitis, a dose-dependent adverse effect seen in roughly 3 to 4% of long-term transplant recipients and one that presents more subtly in older adults 8.

Renal Function Adjustment

Sirolimus itself is not renally cleared, so dose reduction for low eGFR is not pharmacokinetically required. The concern is different: older patients with eGFR <30 mL/min who are not yet on dialysis often have concurrent proteinuria, and sirolimus can worsen proteinuria by 0.5 to 1.5 g/day through direct podocyte effects 9. A baseline urine protein-to-creatinine ratio should be obtained before starting sirolimus in any patient with eGFR <60 mL/min.

Off-Label Longevity Dosing in Adults 65 and Older

This is the fastest-growing area of sirolimus prescribing, and also the least standardized. The mechanistic rationale is solid: mTORC1 inhibition with rapamycin extends lifespan in every model organism tested, including mice given the drug starting at 20 months of age (roughly equivalent to age 60 in humans) 10.

The translation to humans is still being defined. No large randomized controlled trial has yet reported a mortality benefit in healthy older adults. What exists is a growing body of smaller trials, observational data, and the 2024 PEARL study.

The PEARL Trial (Aging Cell, 2024)

The PEARL trial enrolled 115 healthy adults aged 50 to 85 and randomized them to sirolimus 5 mg once weekly, 10 mg once weekly, or placebo for 8 weeks 11. At the 8-week primary endpoint, participants receiving 5 mg weekly reported significantly improved self-rated health scores compared with placebo (P<0.05). The 10 mg arm showed a trend toward improved influenza vaccine antibody titers, though the difference did not reach statistical significance in this sample size.

Adverse events were mild. Mouth sores occurred in 8% of the 10 mg group vs. 2% of placebo. No participant in either active arm developed sirolimus-associated pneumonitis or required dose reduction. Mean trough concentrations at steady state were 4.1 ng/mL in the 5 mg group and 8.2 ng/mL in the 10 mg group.

The PEARL data suggest a practical starting framework for off-label geriatric use: begin at 1 to 2 mg once weekly, titrate by 1 mg every 4 weeks, and target a trough of 3 to 6 ng/mL drawn on the morning of the next scheduled dose (i.e., 7 days after the last dose). This keeps exposure within the range associated with benefit in PEARL while staying below the 8 ng/mL threshold linked to increased adverse effects.

Dosing Frameworks in Current Practice

Off-label longevity prescribers largely follow one of two approaches. The first is fixed low-dose, typically 1 to 3 mg once weekly, without routine trough monitoring. The second is trough-guided titration starting at 2 to 5 mg once weekly with trough measurement at week 3 or 4. Neither approach is yet validated in a powered randomized trial specifically in adults over 65. The PEARL authors themselves note the trial was not powered to detect differences in objective biomarkers of aging.

Why Weekly Dosing May Be Preferable in Older Adults

Daily mTOR inhibition suppresses both mTORC1 (the target for longevity) and mTORC2 (involved in insulin signaling and immune homeostasis). Intermittent dosing may preferentially inhibit mTORC1 while allowing mTORC2 to recover between doses 12. In older adults already at higher baseline risk for impaired glucose tolerance, preserving mTORC2 function is not a minor consideration. A 2014 analysis by Lamming et al. In Science showed that chronic sirolimus treatment in mice produced insulin resistance through mTORC2 disruption, an effect that was attenuated with intermittent dosing 12.

Monitoring Protocol for Geriatric Patients

Older adults on sirolimus need a more structured monitoring schedule than younger transplant or longevity patients. Falls, infection, and wound healing impairment are the three highest-consequence risks in this population.

Laboratory Monitoring Schedule

| Timepoint | Tests | |---|---| | Baseline | CMP, CBC, lipid panel, urine PCR, HbA1c, sirolimus trough (if converting from another agent) | | Week 1 | CBC (thrombocytopenia screen), sirolimus trough | | Week 4 | CBC, CMP, sirolimus trough, lipid panel | | Months 3, 6, 12 | Full panel including lipids, urine PCR, sirolimus trough | | Annually | Chest imaging if any respiratory symptoms; ophthalmology if on long-term calcineurin inhibitor |

Sirolimus raises LDL cholesterol in a dose-dependent fashion. The CONVERT trial (N=830) found that patients switched to sirolimus from calcineurin inhibitors had a mean LDL increase of 13 mg/dL at 12 months 13. In older adults with pre-existing cardiovascular disease, this warrants either pre-emptive statin therapy or closer lipid surveillance.

Infection Risk

MTOR inhibition blunts T-cell proliferative responses. In adults over 65, who already experience immunosenescence, this compounds background infection vulnerability. The KDIGO 2022 guideline recommends pneumococcal vaccination (PCV20 or PCV15 followed by PPSV23) and annual influenza vaccination for all immunosuppressed transplant recipients 7. These recommendations apply equally to older adults using sirolimus off-label, though adherence in the longevity prescribing space is not systematically tracked.

Fall and Fracture Risk

Sirolimus has been associated with impaired wound healing and, in some case series, peripheral edema in up to 12% of patients 14. Edema increases fall risk in older adults. A baseline fall-risk assessment using the CDC STEADI (Stopping Elderly Accidents, Deaths, and Injuries) tool is appropriate before initiating sirolimus in any patient over 65 15.

Drug-Drug Interactions Relevant to Older Adults

The interaction profile of sirolimus is one of the most clinically important pharmacological considerations in geriatric prescribing.

CYP3A4 Inhibitors (Raise Sirolimus Levels)

Several drugs commonly prescribed to older adults are strong CYP3A4 inhibitors. Diltiazem 180 mg/day raises sirolimus AUC by approximately 60% 5. Fluconazole and ketoconazole can increase sirolimus exposure by 3- to 10-fold. Clarithromycin, frequently used for respiratory infections in older adults, is a strong inhibitor that mandates a 50 to 75% sirolimus dose reduction if co-administration is unavoidable.

CYP3A4 Inducers (Lower Sirolimus Levels)

Rifampin reduces sirolimus AUC by approximately 82% 6. St. John's Wort, used by 12 to 14% of older adults for mood support according to NHANES data 16, is a moderate CYP3A4 inducer that may reduce trough concentrations by 30 to 50%. A thorough supplement history is not optional in this age group.

Grapefruit

Grapefruit and grapefruit juice inhibit intestinal CYP3A4 and can raise sirolimus Cmax by 30 to 40%. Patients should avoid grapefruit entirely while on sirolimus 6.

Practical Starting Dose Recommendations by Clinical Context

No single dose fits all geriatric patients. The appropriate starting point depends on the clinical indication, renal function, and current medication list.

Renal Transplant (De Novo, Age 65+)

• Loading dose: 3 mg (half the standard 6 mg load) on day 1
• Maintenance: 1 mg/day, titrate by 0.5 mg every 5 to 7 days based on trough
• Target trough months 1 to 3: 4 to 8 ng/mL (lower end of standard range)
• Target trough beyond month 3: 4 to 6 ng/mL

Conversion from Calcineurin Inhibitor (Age 65+)

• Initiate sirolimus at 2 to 3 mg/day while tapering calcineurin inhibitor over 4 to 6 weeks
• Check trough at day 5 post-initiation, then weekly for 4 weeks
• Anticipate LDL rise; consider initiating low-to-moderate intensity statin concurrently 13

Off-Label Longevity (Age 65+, No Transplant)

• Start: 1 mg once weekly for 4 weeks
• Titrate: increase to 2 mg once weekly if trough at week 3 is <2 ng/mL and tolerability is confirmed
• Maximum: 6 mg once weekly without specialist oversight; some longevity physicians use up to 10 mg weekly (as in PEARL) with trough monitoring
• Discontinue consideration: any new pulmonary symptoms, unexplained thrombocytopenia below 100,000/µL, or wound-healing failure

Deprescribing Considerations

Sirolimus does not require a taper in most longevity protocols; intermittent dosing means steady-state is never fully reached at once-weekly intervals. For transplant patients, stopping sirolimus abruptly carries acute rejection risk and should only occur under nephrology supervision with a planned transition to an alternative agent 7.

In older adults with new frailty, significant cognitive decline, or life expectancy under 12 months, the benefit-risk calculation for continuing sirolimus shifts substantially. Infection risk, wound-healing impairment, and the monitoring burden are all costs that may outweigh potential longevity benefit in patients with limited functional reserve. Geriatric assessment using validated tools like the Clinical Frailty Scale (CFS) should inform this decision 17.

Special Populations Within the 65+ Group

Age 75 and Older

Adults over 75 are significantly underrepresented in sirolimus trial data. The PEARL trial's oldest subgroup (age 75 to 85) numbered only 18 participants across both active arms, too few for subgroup inference. Pharmacokinetic modeling suggests this group may need starting doses 25 to 30% lower than the 65 to 74 subgroup given compounding reductions in CYP3A4 activity and hepatic blood flow.

Low Body Weight

Sirolimus trough concentration correlates inversely with body weight. Patients under 40 kg (not uncommon in very old women) may reach supratherapeutic troughs on doses that are routine in heavier patients. Weight-based dosing (0.1 to 0.2 mg/kg once weekly for longevity) is a reasonable alternative for patients under 50 kg.

Concurrent Diabetes

Sirolimus impairs insulin signaling through partial mTORC2 disruption with chronic dosing 12. Older adults with type 2 diabetes on sirolimus should have HbA1c checked at baseline and every 3 months for the first year. If HbA1c rises more than 0.5 percentage points from baseline, the sirolimus dose should be reviewed before adjusting antidiabetic therapy.